MedTrace Logo

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)

NCT05164003 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacodynamic of CORETOX® in the treatment of post-stroke upper limb spasticity

Conditions

  • Muscle Spasticity

Interventions

DRUG

CORETOX®

Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.

DRUG

BOTOX®

Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-17
Primary Completion
2017-09-29
Completion
2017-09-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05164003 on ClinicalTrials.gov